Research any topic before you write.

Find related topics. | Discover entities. | See connections. | Build a topical map.

Ruxolitinib: Community, Culture, Applications & Research

Ruxolitinib (sold under the brand names Jakafi and Jakavi among others, and as Opzelura in cream form) is a medication used for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative neoplasm that affects the bone marrow; polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; and…

Language: English [EN]
Use the mouse wheel or two fingers (on touchscreens) to zoom in and out of the map.
100%
More settings
100% 100% 100% 100% 100%

Ruxolitinib topic overview

The analysis highlights Community, Culture, Applications and Research as prominent areas in the source structure around Ruxolitinib.

Related topics
51
Source areas
6
Connected nodes
57
Extracted relationships
50
Related term clusters
14
Bridge connections
57

What this topic covers Research coverage

Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.

Side effects · 19 topics
Overview · 11 topics
Research · 9 topics
Mechanism of action · 5 topics
Medical uses · 4 topics
Society and culture · 3 topics

Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.

Key facts & relationships

High-confidence facts extracted from structured source data. Use them as anchors for further research.

3D model (JSmol)
Interactive image
AHFS/Drugs.com
Monograph
ATC code
L01EJ01 (WHO) D11AH09 (WHO)
Bioavailability
95%
CAS Number
941678-49-5 Y
ChEMBL
ChEMBL1789941 N

Start with your topic. Discover where to go next.

Explore different angles and find fresh ideas to shape your next piece of content.

Explore all related topics Closing gaps

Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.

Overview

Medical uses

Side effects

Mechanism of action

Society and culture

Research

For the semantics nerds

You can skip this section if you’re here for content ideas and keyword inspiration.

Advanced semantic analysis

How Ruxolitinib connects Entity context

The extracted context around Ruxolitinib shows recurring relationship patterns in the source. For example, Ruxolitinib → COMFORT-I, COMFORT-II Trials, Drug Administration, FDA, Food, In November, RESPONSE Another extracted example is Ruxolitinib → AU: S4 (Prescription only), CA: ℞-only, EU: Rx-only, UK: POM (Prescription only), US: ℞-only. Use these groups to spot repeated connection types before inspecting the individual relationships.

Ruxolitinib

Top relations

related to Legal status · 7
Ruxolitinib → COMFORT-I, COMFORT-II Trials, Drug Administration, FDA, Food, In November, RESPONSE
Legal status · 5
Ruxolitinib → AU: S4 (Prescription only), CA: ℞-only, EU: Rx-only, UK: POM (Prescription only), US: ℞-only
related to Mechanism of action · 5
Ruxolitinib → JAK, JAK1, JAK2, Janus, STATs
KEGG · 2
Ruxolitinib → as salt: D09960 N, D09959 N
is a · 2
Ruxolitinib → first FDA-approved pharmacologic treatment to address repigmentation in vitiligo patients.The crystal structure of ruxolitinib and of its dihydrate form are known, Janus kinase inhibitor
related to Medical uses · 2
Ruxolitinib → European Union, United States
3D model (JSmol) · 1
Ruxolitinib → Interactive image
AHFS/Drugs.com · 1
Ruxolitinib → Monograph
ATC code · 1
Ruxolitinib → L01EJ01 (WHO) D11AH09 (WHO)
Bioavailability · 1
Ruxolitinib → 95%

Important terminology

Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.

Important terminology

treatment myelofibrosis vitiligo cream disease approved united states opzelura indicated graft-versus-host brand side effects medical us name jakafi jakavi include

Ruxolitinib relationships Subject–Predicate–Object triples

TTTA extracted 50 structured relationships around Ruxolitinib. Examples in this analysis include Ruxolitinib → 3D model (JSmol) → Interactive image and Ruxolitinib → AHFS/Drugs.com → Monograph. The table shows each extracted connection, where it came from and its confidence.

SubjectPredicateObjectConfidenceSrc
Ruxolitinib3D model (JSmol)Interactive image1.00infobox
RuxolitinibAHFS/Drugs.comMonograph1.00infobox
RuxolitinibATC codeL01EJ01 (WHO) D11AH09 (WHO)1.00infobox
RuxolitinibBioavailability95%1.00infobox
RuxolitinibCAS Number941678-49-5 Y1.00infobox
RuxolitinibChEMBLChEMBL1789941 N1.00infobox
RuxolitinibChemSpider25027389 Y1.00infobox
RuxolitinibCompTox Dashboard (EPA)DTXSID102409301.00infobox
RuxolitinibDrugBankDB08877 Y1.00infobox
RuxolitinibElimination half-life2.8-3 hours1.00infobox
RuxolitinibExcretionUrine (74%), faeces (22%)1.00infobox
RuxolitinibFormulaC17H18N61.00infobox
RuxolitinibIUPHAR/BPS56881.00infobox
RuxolitinibKEGGD09959 N1.00infobox
RuxolitinibKEGGas salt: D09960 N1.00infobox
RuxolitinibLegal statusAU: S4 (Prescription only)1.00infobox
RuxolitinibLegal statusCA: ℞-only1.00infobox
RuxolitinibLegal statusUK: POM (Prescription only)1.00infobox
RuxolitinibLegal statusUS: ℞-only1.00infobox
RuxolitinibLegal statusEU: Rx-only1.00infobox
RuxolitinibLicense dataUS DailyMed: Ruxolitinib1.00infobox
RuxolitinibMedlinePlusa6120061.00infobox
RuxolitinibMetabolismLiver (mainly CYP3A4-mediated)1.00infobox
RuxolitinibMolar mass306.373 g·mol−11.00infobox
RuxolitinibOther namesINCB018424, INC4241.00infobox
RuxolitinibPDB ligandRXT (PDBe, RCSB PDB)1.00infobox
RuxolitinibPregnancy categoryAU: C1.00infobox
RuxolitinibProtein binding97%1.00infobox
RuxolitinibPubChem CID251267981.00infobox
RuxolitinibRoutes of administrationBy mouth, topical1.00infobox

Related concept clusters Related term clusters

The concept neighborhoods around Ruxolitinib bring nearby vocabulary together. In this analysis, examples include Treatment, Cream and Steroid-refractory. Use the clusters to find adjacent concepts and terminology that may deserve separate research.

  • Ruxolitinib
    • Treatment
    • Cream
    • Steroid-refractory
    • Indicated
    • Opzelura
    • Vitiligo
    • Disease
    • States
    • United
    • Sold
    • Acute
    • Adults
  • ruxolitinib
    • Treatment
    • Cream
    • Steroid-refractory
    • Indicated
    • Opzelura
    • Vitiligo
    • Disease
    • States
    • United
    • Sold
    • Acute
    • Adults
  • myelofibrosis
    • Jak
    • Effects
    • Opzelura
    • Side
    • Treatment
    • Ruxolitinib
    • Hydroxyurea
    • Sold
    • Thrombocytopenia
    • Union
    • Acute
    • Adults
  • polycythemia vera
    • Hydroxyurea
    • Form
    • Jakafi
    • Jakavi
    • Sold
    • Thrombocytopenia
    • Acute
    • Adults
    • Brand
    • Common
    • Steroid-refractory
    • Treatment
  • graft-versus-host disease
    • Disease
    • Graft-versus-host
    • Steroid-refractory
    • Chronic
    • Therapy
    • Us
    • Include
    • Treatment
    • Ruxolitinib
    • Form
    • Hydroxyurea
    • Jakafi
  • side effects
    • Side
    • Thrombocytopenia
    • Common
    • Include
    • Myelofibrosis
    • Jakafi
    • Jakavi
    • Union
    • Adults
    • Chronic
    • European
    • Medical
  • european medicines agency
    • Union
    • Adults
    • Medical
    • Use
    • Indicated
    • Opzelura
    • Vitiligo
    • States
    • United
    • Treatment
    • Jakafi
    • Jakavi
  • medical uses
    • States
    • United
    • Name
    • Use
    • Opzelura
    • Sold
    • Union
    • European
    • Treatment
    • Ruxolitinib
    • Adults
    • Chronic

Connections between topic areas Semantic bridges

For Ruxolitinib, one of the stronger structural bridges in this analysis connects Ruxolitinib with Side effects. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.

Min side: 3
Ruxolitinib — Side effects · splits 38 ⟂ 20
Ruxolitinib — Overview · splits 46 ⟂ 12
Ruxolitinib — Research · splits 48 ⟂ 10
Ruxolitinib — Mechanism of action · splits 52 ⟂ 6
Ruxolitinib — Medical uses · splits 53 ⟂ 5
Ruxolitinib — Society and culture · splits 54 ⟂ 4

Map overview Semantic statistics

Ruxolitinib

Nodes58
Edges57
Triples50
Avg. degree1.97
Density0.034483
Components1

Source & methodology

TTTA analyzes the structure around Ruxolitinib to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as Community, Culture, Applications & Research, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.

Source: Wikipedia — Ruxolitinib · EN edition · Analysis: TopicsToTalkAbout

For writers, content strategists, SEOs, marketers and creators — from quick topic research to advanced semantic analysis.

Monitor your Domain Rating with FrogDR